<DOC>
	<DOCNO>NCT02262338</DOCNO>
	<brief_summary>AGT-182 fusion protein contain idursulfase intend deliver enzyme peripherally brain , administer intravenously . This study safety dose range study obtain safety exposure data , well information biological activity investigational drug .</brief_summary>
	<brief_title>Safety Dose Ranging Study Insulin Receptor MoAb-IDS Fusion Protein Patients With Hunter Syndrome</brief_title>
	<detailed_description>This sequential , open-label , dose escalation , multi-dose study adult Hunter syndrome . Two dose level , assume tolerability , plan sequentially , safety data previous cohort review prior escalation next high dose cohort . Subjects receive weekly dos AGT-182 8 week ERT-naive agree 6-week ERT washout , 13 week currently take ERT agree washout .</detailed_description>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Male age 18 year old Diagnosis Hunter Syndrome ( document fibroblast leukocyte IDS enzyme activity level le 10 % low limit normal range measure laboratory level enzyme deficiency together presence pathogenic mutation IDS gene documentation normal enzymatic activity least 1 sulfatase . ) Must fall one follow group : currently receive standard enzyme replacement therapy ( ERT ) willing discontinue study duration , take AGT182 instead receive standard ERT least 3 month elevate uGAGs least 3.5 fold agerelated normal study screen never receive ERT Voluntary write consent Sexually mature male must advise use medically accept method contraception throughout study . Refusal complete screening/baseline evaluation Receipt investigational drug within prior 90 day Any medical condition circumstance may significantly interfere study compliance Clinically significant spinal cord compression , evidence cervical instability Known hypersensitivity idursulfase component AGT182 Known nonresponsive standard ERT treatment ( i.e. , high uGAG value despite take full dose standard ERT ) History diabetes mellitus hypoglycemia Contraindication lumbar puncture , patient agree optional assessment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS II</keyword>
	<keyword>Hunter Syndrome</keyword>
</DOC>